[Thyroid and osteoporosis].
Data indicate that in overt hyperthyroidism the equilibrium of the synthetic and degradation processes suffers a change in the bone, there exists an increased turnover with a predominance of resorption. Recently many new sensitive markers have been developed which are correctly reflecting the altered bone metabolism in hyperthyroidism. It is demonstrated that overt hyperthyroidism is a risk factor for osteoporosis. Osteopenia improves after the successful treatment of the disease, however, a complete restitution may ensue only after years. Lately attention has been focused on subclinical hyperthyroidism. Findings indicate that osteoporosis can not be demonstrated in premenopausal women with endogenous subclinical hyperthyroidism, while this disease may play a role in the development of osteopenia in part of post menopausal women. Likewise, in a postmenopausal women receiving levothyroxine replacement therapy an increased circumspection is required and it is recommended to avoid the administration of a levothyroxine dose suppressing TSH secretion. When suppression treatment is necessary the administration of the lowest, but the TSH secretion already suppressing levothyroxine dose is proposed.
Földes
J
J
Semmelweis Orvostudományi Egyetem, I. sz. Belklinika, Budapest.
Lakatos
P
P
D015519:Bone Density / Q000187:drug effects; D005598:Fractures, Spontaneous / Q000209:etiology; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D010024:Osteoporosis / Q000209:etiology* / Q000503:physiopathology; D013974:Thyroxine / Q000009:adverse effects* / Q000627:therapeutic use
D013974:Thyroxine
Pajzsmirigy és osteoporosis.